MedPath

Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death

Active, not recruiting
Conditions
Endocrine Neoplasia
Pheochromocytoma
Primary Aldosteronism
Adrenal Cushing Syndrome
Interventions
Diagnostic Test: Adrenal aldosterone synthase (CYP11B2) staining
Diagnostic Test: Adrenal cortisol synthase (CYP11B1) staining
Diagnostic Test: Histopathological analysis
Registration Number
NCT05446779
Lead Sponsor
Helsinki University Central Hospital
Brief Summary

Sudden Cardiac Death is a leading cause of mortality and remains a major public health burden worldwide. Cardiac arrest due to coronary heart disease explains a large proportion of the cases, but if autopsy is not performed the exact underlying cause remains obscure in many adults who face sudden death outside heath care organizations. The investigators aim to find proof that primary aldosteronism is a risk factor for sudden death and to characterize the prevalence of adrenal pathology in sudden death of undetermined cause in a case-control study. In addition, the study aims to characterize the prevalence of other adrenal pathology i.e. silent adenomas, cortisol-producing adenomas and pheochromocytomas in sudden death. The investigators also seek evidence that other endocrine hormone overproduction-causing diseases are more prevalent in persons with sudden death compared with those experiencing traumatic or suicidal death sudden death.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria

Consecutive patients with out-of-hospital, sudden death

Exclusion Criteria
  1. Estimated time from death to refrigerator more than 24-48 hours and in the refrigerator time more than 7 days (susceptibility to excessive tissue breakdown)
  2. Terminal disease
  3. Institutionalized patients

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Sudden deathHistopathological analysisUnexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
ControlHistopathological analysisDeath because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
Sudden deathAdrenal cortisol synthase (CYP11B1) stainingUnexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
ControlAdrenal aldosterone synthase (CYP11B2) stainingDeath because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
Sudden deathAdrenal aldosterone synthase (CYP11B2) stainingUnexpected witnessed death occurring within an hour of the onset of symptoms in a person with or without previously known cardiac disease without an extra-cardiac cause, or unexpected unwitnessed death without extra-cardiac cause occurring in the previous 24 hours
ControlAdrenal cortisol synthase (CYP11B1) stainingDeath because of an exogenic reason for sudden death such as trauma or suicide as a control group i.e. non-disease-induced sudden death
Primary Outcome Measures
NameTimeMethod
CYP11B1 staining in adrenal glandsThrough study completion, an average of 2 years

Histopathological diagnosis of the autopsy

CYP11B2 staining in adrenal glandsThrough study completion, an average of 2 years

Histopathological diagnosis of the autopsy

Secondary Outcome Measures
NameTimeMethod
CYP11B2 staining in adrenal glandsThrough study completion, an average of 2 years

Histopathological diagnosis of the autopsy

Pheochromocytoma or paragangliomaThrough study completion, an average of 2 years

Histopathological diagnosis of the autopsy

Neuroendocrine tumorThrough study completion, an average of 2 years

Histopathological diagnosis of the autopsy

Trial Locations

Locations (1)

Endocrinology, Helsinki University Hospital and University of Helsinki

🇫🇮

Helsinki, Finland

© Copyright 2025. All Rights Reserved by MedPath